Successful Completion of DSMB Review of Phase 3 FSGS Trial
Filed with ASX · · 4 pages · English
Story so far
Earlier from Dimerix
- FDA Confirms Inclusion of Paediatrics in ACTION3 Study
- DMX-200 FSGS Phase 3 Trial Part 1 Recruitment Achieved
- CLARITY 2.0 COVID-19 Study Outcome
- Chair address and CEO presentation to AGM
- Dimerix Receives A$6.0M R&D Tax Incentive Rebate
Later from Dimerix
- DXB to Receive $2.8m in Prepayment of R&D Tax Incentive
- Half-Year Financial Report & Appendix 4D - 31 December 2022
- Voluntary Suspension
- Entitlement offer and Convertible Note to raise $12 million
- Reinstatement to Official Quotation
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix